

CD24

Catalog # PVGS1922

Product Information

| | |
|---------------------------------------|--|
| Primary Accession Species | P25063-1 Human |
| Sequence | Ser27-Gly59 |
| Purity | > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
| Endotoxin Level | Less than 1EU per μ g by the LAL method. |
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized CD24, His & Avi, Human at 1 μ g/ml (100 μ l/well) on the plate can bind Anti-CD24 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System | HEK293 |
| Theoretical Molecular Weight | 6.5 kDa |
| Formulation Reconstitution | Lyophilized from a 0.22 μ m filtered solution in PBS, (pH 7.4). Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μ g/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |

Additional Information

| | |
|--------------------------|---|
| Target Background | CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers. |
|--------------------------|---|

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.